All In MedTech

Device Trial Radar · NCT07538609

The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Aug 25, 2026

Primary completion

May 2029

Study completion May 2031

Sponsor

Lead sponsor
W.L.Gore & AssociatesNot on our public-company list
Sponsor type
Industry
First posted
Apr 20, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, multicenter, single-arm post-market clinical study to evaluate the GORE® VIABAHN® FORTEGRA Venous Stent in real-world use.

Conditions

  • Venous Thromboses
  • Venous Disease
  • Venous Leg Ulcer
  • Venous Stasis
  • Venous Ulcer
  • Venous Stenosis
  • Venous Occlusion
  • Vein Thrombosis

Interventions

  • GORE® VIABAHN® FORTEGRA Venous StentDevice

    Treatment with the GORE® VIABAHN® FORTEGRA Venous Stent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary effectiveness as assessed by primary patencyTime frame: 12 months
  2. Primary safety as assessed by SAEsTime frame: 30 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Vascular Care Connecticut

    Darien, Connecticut · Recruiting

  • Medstar Washington Haspital Center

    Washington D.C., District of Columbia · Recruiting

  • Baylor Research Institute

    Dallas, Texas · Recruiting

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.